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Abstract
HIV-mediated CD4 depletion is the hallmark of AIDS and is the most reliable predictor of disease
progression. While HIV replication is associated with CD4 depletion in general, plasma viremia by
itself predicts the rate of CD4 loss only minimally in untreated patients. To resolve this paradox, I
hypothesize the existence of a subpopulation of R5X4-signaling viruses. I also suggest that the gradual
evolution and emergence of this subpopulation are largely responsible for the slow depletion of
peripheral CD4 T cells.
Background
The human immunodeficiency virus (HIV) infects CD4 T
cells and causes CD4 depletion which leads to the devel-
opment of AIDS. In the spectrum of clinical signs associ-
ated with HIV infection, CD4 depletion is a hallmark and
is one of the most powerful predictors of disease progres-
sion. On the other hand, the level of viral replication, as
reflected by plasma viral RNA load, has also been sug-
gested to directly predict progression to AIDS and death
[1]. Nevertheless, the relationship between plasma
viremia and CD4 depletion rate has been a subject of
debate [2]. While it is certain that a strong correlation
between viral load and CD4 depletion exists when plasma
viremia is grouped into different categories (e.g. < 500
copies/ml, 501–3000 copies/ml, >30,000 copies/ml etc.)
[1,3], at the individual level, the presenting viral load
poorly predicts the rate of CD4 depletion in untreated
patients [2,4]. To resolve this paradox, here I propose a
new hypothesis from a co-receptor signaling perspective
based on our recent studies [5]. As shown in Figure 1, I
hypothesize that HIV-1 gp120-CXCR4 signaling plays a
major role in the gradual depletion of peripheral CD4 T
cells during chronic HIV infection.
In this model, I separate the disease course into three
phases: (1) primary HIV replication, (2) priming, and (3)
delayed HIV replication. The primary phase largely
involves the efficient replication of CCR5-utilizing, M-
tropic viruses such as those replicating in the GI tract [6].
In the second phase, with immune suppression or the
consumption of most of the available CCR5 target T cells,
viral replication is reduced to a low level. This low-level
ongoing viral replication serves as a reservoir that supplies
viral mutants to prime the immune system for new target
cells. Early on in the priming phase, limited mutations
such as one or two amino acid changes in the V3 loop of
the viral envelope may give rise to the first CXCR4-prim-
ing virus. These small numbers of early viruses may still
use CCR5 for entry and replication but can engage
CXCR4. This CXCR4 binding may not permit viral entry
since successful fusion and entry often require more than
two mutations or even mutations outside of the V3 loop
[7]. Other virological obstacles may also play a role in pre-
venting the quick emergence of viruses with the X4 phe-
notype [8]. Nevertheless, these early CXCR4-priming
viruses (R5X4-signaling viruses) can trigger signal transduc-
tion in CXCR4 cells without actually infecting and repli-
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signaling may mediate CD4 T cell dysfunction and con-
tribute to chronic immune activation, gradually shifting
these otherwise restrictive cells towards the direction of
permissiveness. With continued engagement of the
CXCR4 receptor, the priming event may eventually lead to
the emergence of the X4 viral phenotype and its viral rep-
lication in some patients. The newly emerged CXCR4-uti-
lizing, T-tropic viruses would then find a large pool of
targets and initiate a new phase of viral replication, the
third delayed replication phase, which could result in
rapid CD4 depletion and fast progression to AIDS [9]. In
some patients, the full X4 phenotype may never arise, but
the X4 priming could remain an ongoing process that
would provoke slow CD4 depletion and disease progres-
sion.
The central tenets of this new signaling model are the
hypothetical existence of the R5X4-signaling viruses during
chronic infection and the direct association of these
viruses with CD4 depletion. The R5X4-signaling viruses are
predicted to be a minority during the chronic phase with
no strong replication or selection advantage over other R5
viruses [10], largely because of the continuous use of
CCR5-positive cells for replication. Moreover, the signal-
ing and depletion of CD4 T cells by the R5X4-signaling
mutants are likely to be loosely correlated with the overall
predominance of R5 viruses which are less pathogenic to
peripheral CD4 T cells in general. Nevertheless, the emer-
gence of the R5X4-signaling viruses does depend on the pool
of R5 viruses; thus, while HIV-1 replication is overall asso-
ciated with CD4 depletion [1], the use of total plasma
viral RNA load, a measurement of mostly R5 viruses, is a
poor predictor of the slow CD4 loss in patients [2]. The
very existence of the hypothetical R5X4-signaling subpopula-
tion that can directly cause CD4 loss would be a reasona-
ble explanation for the observed paradoxical relationship
between total viral load and CD4 depletion [1,2].
Discussion
The different T cell targets of M-tropic and T-tropic viruses
The natural course of HIV infection almost always starts
with the robust replication of the CCR5-ultilizing M-
tropic viruses [6,11,12]. The R5 viruses can quickly infect,
replicate and kill a large number of target cells such as the
active memory CD4 T cells present in the GI tract
[6,11,12]. This early process occurs in both HIV-1 infec-
tion of humans [6,12] and in the pathogenic and non-
pathogenic SIV infection of monkeys [11], and can result
in lasting pathogenic insults [13] to or non-pathogenic
effects [14,15] on the immune system. With the onset of
the asymptomatic phase following the acute infection,
viral diversification occurs. In about 50% of infected
patients (mostly subtype-B infection), there is a viral
switch in the co-receptor usage, from CCR5 to CXCR4, at
late stages of disease. This switch correlates with faster
CD4 depletion and more rapid disease progression
towards AIDS [9,16-19]. The late emergence of the
CXCR4-utilizing viruses may be a reflection of the restric-
tive nature of the X4 viral target cells. In the human
immune system, a majority of CD4 T cells in the periph-
eral blood are CXCR4-positive, resting CD4 T cells. These
The co-receptor signaling model of HIV pathogenesis in peripheral CD4 T cellsFigure 1
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come to replicate. Firstly, the viral envelope has to be
mutated to engage the CXCR4 receptor [20], and the
mutations have to accumulate to a sufficient degree to per-
mit successful viral entry [7,8]. Secondly, the virus has to
modulate the immune system, either by inducing
cytokines [21-23] or facilitating transient immune activa-
tion to permit viral integration [24-29]. Even with success-
ful integration, the virus has to induce or rely on chronic
immune activation to maintain stable gene expression
and viral production [22,23,30]. Recently, we demon-
strated that the static cytoskeletal actin in resting CD4 T
cells is also a barrier for viral intracellular migration [5].
To overcome this restriction, the virus has to rely on signal
transduction via the viral envelope binding to CXCR4,
which triggers the activation of an actin depolymerization
factor cofilin in resting T cells. This cofilin activation
increases cortical actin treadmilling and actin dynamics,
permitting viral migration across the cortical actin barrier
[5].
Given the critical role that CXCR4 signaling plays in HIV
infection of peripheral CD4 T cells, it is possible that HIV-
mediated aberrant signalling through CXCR4 may con-
tribute to viral pathogenesis in these cells. It has long been
recognized that the residual CD4 cells in HIV-infected
subjects have multiple functional abnormalities such as
anergy [31,32], loss of T helper function [33], and abnor-
mal T cell homing and migration [34,35], all of which
result from the bystander effect [36]. These T cell abnor-
malities suggest that although they are not directly
infected, these residual CD4 T cells may have been
engaged by viruses or viral factors, and their signaling
responses to environmental stimuli have been profoundly
altered.
Supporting evidence from bioinformatics studies of the 
evolution of the HIV envelope protein
In contrast to the R5 viruses, the capacity of the late-
emerging X4 viruses to cause rapid CD4 depletion clearly
demonstrates the pathogenic importance of the CXCR4-
engaging viruses [9,16-19]. Interestingly, by using bioin-
formatics approaches such as neural networks [37], PSSM
[38,39] or 11/25 genotype [39-43], the potential of the R5
virus to switch to the more pathogenic X4 virus can be pre-
dicted based on the charged residues within the V3 loop,
particularly at the 11 and 25 positions of V3. Remarkably,
even though approximately 50% of patients do not actu-
ally acquire the X4 phenotype ever in their disease, the V3
genotypes were found to be associated with more rapid
CD4 depletion and faster disease progression [44]. The
predictive value of the X4 genotypes for CD4 depletion
presumably hinges upon the occurrence of the X4 pheno-
type. Yet, it is very possible that these X4 genotypes may
reflect the actual capacity of the viral envelopes to engage
and signal through CXCR4. Therefore, the direct correla-
tion of CD4 depletion with the X4 genotypes in the
absence of the X4 phenotype is a strong indication of the
possible existence of the R5X4-signaling viruses. As a matter of
fact, a recent study using massive pyrosequencing of the
V3 loop has found that clusters of the R5 proviral
genomes harboured in patients' monocytes carry muta-
tions with the X4 genotypes [45]. Similar R5 genotypic
evolution was also observed even in patients maintaining
exclusively the R5 viruses [46]. In the absence of the R5-
to-X4 phenotypic switch, the R5 phenotype does evolve
with disease progression in properties such as a decreasing
sensitivity to the neutralization by CC chemokines [47]
and an increasing capacity for direct and DC-SIGN-medi-
ated trans-infection of T cells [46]. In addition, it has also
been shown that in the peripheral blood mononuclear
cells of infected patients, different sub-populations of
infected cells co-exist, and some of these cells, such as
infected monocytes and memory T cells, have a slow
decay rate [48]. These cells may serve as the seeds for the
development of the R5X4-signaling phenotype.
The balance between gp120 priming T cells and triggering 
apoptosis
In addition to transducing signals to promote HIV infec-
tion [5,49-51], HIV envelope binding to the chemokine
co-receptors has also been suggested to trigger apoptosis
of CD4 T cells [52-56]. Even before the identification of
the chemokine co-receptors, gp120 was proposed to trig-
ger activation-dependent T cell apoptosis through the
CD4 receptor [57-59]. This suggestion was based on a
similar mechanism observed in the activation of murine
lymphocytes in which pre-stimulation of the CD4 recep-
tor triggered apoptosis when the cells were also activated
through the T cell receptor [60]. It appears that engage-
ment of the CD4 receptor alone, either by the R5 or X4
viruses, may not be sufficient to trigger apoptosis; CD4
signaling promotes apoptosis largely in the presence of
signals that also activate CD4 T cells [57-59]. The R5-
viruses may induce apoptosis through CCR5 in active
memory CD4 T cells [61]. The majority of peripheral rest-
ing CD4 T cells, however, have either no CCR5 or low lev-
els of CCR5 receptor. It is possible that the apoptotic
process in resting CD4 T cells is triggered by the X4 viruses
or X4-signaling viruses by binding and signaling through
CXCR4.
HIV envelope-mediated apoptosis has been implicated to
contribute to the depletion of either infected or unin-
fected CD4 T cells [57]. Nevertheless, from a purely viro-
logical point of view, triggering apoptosis, especially at
the earliest time of infection, is a misfortune and is some-
thing that a virus should always avoid. For example, even
the fast replicating, extremely cytolytic viruses such as bac-
ulovirus encode anti-apoptotic proteins to avoid trigger-Page 3 of 6
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latently infected resting CD4 T cells, with a half life as long
as 3 to 4 years [63], were frequently detected to persist in
patients [64-66]. In addition, it has also been shown that
in contrast to triggering apoptosis, the HIV-1 envelope can
induce productive viral replication from the resting CD4 T
cells of HIV-infected patients [51]. Therefore, it is possible
that even though the HIV envelope triggers apoptosis of
CD4 T cells, this may not frequently occur until the X4 sig-
naling viral population reaches a significant level. In other
words, the balance between CXCR4 priming and CXCR4
triggering apoptosis is probably regulated by signal
strength; apoptosis would require higher viral dosages. In
the HIV disease course, initially, low levels of X4 signaling
viruses may prime CD4 T cells for infection, whereas at a
late stage when levels of X4 signaling viruses are high
especially with the emergence of the X4 phenotype, trig-
gering apoptosis may be more common and may directly
contribute to CD4 depletion.
It has also been suggested that HIV-infected cells down-
regulate PD-1, whereas uninfected bystander cells do not
[67]. PD-1 downregulation prevents cells from early
apoptosis. Presumably, this mechanism would enrich
HIV+ CD4 T cells, facilitating the amplification of X4
viruses. Nevertheless, this mechanism probably would
not be in play until the late emergence of the X4 pheno-
type.
Basic characteristics associated with the hypothetic R5X4-
signaling viruses
In the chemokine co-receptor signaling model, the hypo-
thetic R5X4-signaling viruses are proposed to be responsible
for the slow depletion of peripheral CD4 T cells. Experi-
mental demonstration of such R5X4-signaling viruses
requires the establishment of certain basic criteria. Firstly,
the R5X4-signaling viruses are phenotypically R5 viruses. They
should enter CD4+CCR5+ but not CD4+CXCR4+ indicator
cells in co-receptor tropism assays. These viruses should
also demonstrate susceptibility to antagonists specific for
CCR5. Secondly, the envelope protein from the R5X4-signal-
ing viruses should be able to bind to CXCR4 in non-cell-
based in vitro binding assays; this interaction can be com-
petitively inhibited by a CXCR4 antagonist. The ability to
interact with CXCR4 does not equate with the capability
to trigger fusion, which requires the involvement of other
regions in addition to the V3 loop of gp120. There are
likely varying degrees of affinity for CXC4 among the
R5X4-signaling viruses. Thirdly, the R5X4-signalingviruses should
demonstrate the ability to trigger signal transduction
through CXCR4 in resting CD4 T cells. The signaling may
also be shut down by a CXCR4 antagonist. The issue is
complex because CXCR4 signaling is known to be diverse
and can activate an array of downstream targets such as
Pyk2 [68], PI3K, Akt [69,70], Erk-1/2 [70], and cofilin [5].
It is expected that not every one of these targets is directly
involved in HIV infection and pathogenesis. In addition,
there are also dosage and affinity-dependent differences in
activating specific pathways. For example, at low dosages,
SDF-1 binding to CXCR4 attracts CD4 T cells, whereas at
high dosages, the same binding does the opposite to repel
CD4 cells [35,71]. Therefore, the critical issue becomes
what downstream target should be used as a readout for
measuring CXCR4 signaling at a defined viral dosage. Cur-
rently, we propose coflin as a final readout for measuring
CXCR4 signaling in CD4 T cells because we have demon-
strated that it is a direct downstream target of gp120-
CXCR4 interaction, and its activation facilitates viral
infection. Nevertheless, clinical studies are required to
determine whether activation of cofilin or any other
CXCR4 downstream target is directly associated with CD4
depletion and HIV disease progression. Establishment of
this relationship is an essential step to experimentally
identify the R5X4-signalingsubpopulation.
Conclusion
The co-receptor signaling model implies that the HIV
envelope plays a major role in the slow depletion of
peripheral CD4 T cells. Although HIV directly infects only
a very small percentage of peripheral CD4 T cells (0.2–
16.4 HIV-latently infected cells per 106 resting CD4 T cells
[64]), the ability of the viral envelope to alter T cell func-
tion through signal transduction should not be underesti-
mated. This hypothesis highlights the need for a thorough
examination of the signaling properties of HIV quasispe-
cies in patients. I also speculate that these R5X4-signaling
viruses may cause cofilin activation in resting CD4 T cells
as suggested in our recent studies [5,72]. Conceivably, in
comparison with the use of plasma viral load as a readout,
cofilin activation would be a more direct reflection of
CD4 dysfunction and may serve as an early marker for
predicting CD4 depletion.
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